Brief: Black Diamond Therapeutics Announces FDA Allowance Of IND Application For BDTX-1535

Black Diamond Therapeutics

11/01/2022 12:12

Jan 11 (Reuters) - Black Diamond Therapeutics Inc  BDTX.O :
    * BLACK DIAMOND THERAPEUTICS ANNOUNCES FDA ALLOWANCE OF IND APPLICATION FOR
BDTX-1535, A MASTERKEY INHIBITOR OF EGFR FOR THE TREATMENT OF GLIOBASTOMA AND
NON-SMALL CELL LUNG CANCER
    * BLACK DIAMOND THERAPEUTICS INC - EXPECTS TO INITIATE PHASE 1 STUDY OF
BDTX-1535
IN Q1 OF 2022

Source text for Eikon:  ID:nGNX353sM6 
Further company coverage:  BDTX.O